Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.
Monkeypox outbreak: What you need to know about it?
Mohamad Ali Salloum, PharmD • June 22, 2022
Share
On June 1, 2022, WHO (World Health Organization) stated that More than 550 monkeypox cases have been identified in at least 30 countries.
First of all, What is monkeypox?
It is a zoonotic viral disease native to Africa. Cases usually occur near tropical rainforests, where animals that carry the virus live. Cases in the U.S. are rare and associated with international travel from places where the disease is more common.
Zoonotic means that it can spread between species and in this case from- animals to humans.
It is a member of a virus family called orthopoxvirus. It has 2 distinct strains:
- The Central African (Congo Basin) strain.
- The West African strain.
The Central African strain is known to spread more easily and cause more severe symptoms.
What are the symptoms?
Symptoms of the disease include:
- Skin lesions,
- Fever,
- Body aches.
- Chills
- Swollen lymph nodes
- Exhaustion
The symptoms are similar to smallpox but milder.
Severe cases are seen in patients with immune deficiencies and young children.
Incubation period, the time from infection to onset of symptoms, can range from 5 to 21 days. The illness typically resolves within 2 to 4 weeks.
Is it fatal?
In recent times, the case fatality ratio of monkeypox is around 3-6%.
How is it transmitted?
Although transmission is limited between Humans, it can happen:
- Through close skin contact,
- Bodily fluids,
- Virus-contaminated objects.
In contrast to what was being spread about its transmission method, specialists say that the disease is not an STD (sexually-transmitted disease), however, it can spread via direct contact during sex.
Scientists still lack a lot of data, and that’s why they still can’t confirm how long it’s been spreading.
It’s important to mention that it is thought by WHO that this virus is unlikely to outbreak and turn into a global pandemic like the COVID-19 virus. But again, they are not sure.
Treatments that can be used?
Usually symptoms go away on their own within few weeks, however, some individuals require treatment for recovery. “Tecovirimat (TPOXX), as both oral and IV medication is approved in the U.S. for treating smallpox and oral form in Europe to treat cowpox, monkeypox, and smallpox. The FDA approved brincidofovir (Tembexa) in 2021 to treat smallpox and it was tried with Monkeypox, however, it had poor efficacy.
Is there a vaccine?
There is an approved vaccine for monkeypox and it is called MVA-BN. Unfortunately, it is not widely available. This vaccine is also known as Imvamune, Imvanex or Jynneos) and was approved in 2019 for use in preventing monkeypox.
Even though people who were vaccinated against smallpox will have a certain level of protection against monkeypox, they need to take precautions to protect themselves and the others.
Resources:
List of Services
ABOUT THE AUTHOR
Mohamad-Ali Salloum, PharmD
Share
Recent articles:
Discover the best ways to learn new skills
Stuck in your head? Discover why overthinking feels productive, how it sabotages your performance, and simple ways to shift into real action.
References: Wood W, Quinn JM, Kashy DA. Habits in everyday life: Thought, emotion, and action. J Pers Soc Psychol . 2002;83(6):1281–1297. Wood W, Neal DT. The habitual consumer. J Consum Psychol . 2009;19(4):579–592. Neal DT, Wood W, Labrecque JS, Lally P. How do habits guide behavior? Perceived and actual triggers of habits in daily life. J Exp Soc Psychol . 2012;48(2):492–498. Wood W, Mazar A, Neal DT. Habits and goals in human behavior: Separate but interacting systems. Perspect Psychol Sci . 2021;16(1):1–16. Graybiel AM. Habits, rituals, and the evaluative brain. Annu Rev Neurosci . 2008;31:359–387. Smith KS, Graybiel AM. Habit formation. Dialogues Clin Neurosci . 2016;18(1):33–43. Yin HH, Knowlton BJ. The role of the basal ganglia in habit formation. Nat Rev Neurosci . 2006;7(6):464–476. Graybiel AM. The basal ganglia and chunking of action repertoires. Neurobiol Learn Mem . 1998;70(1–2):119–136. Schultz W. Dopamine reward prediction error coding. Dialogues Clin Neurosci . 2016;18(1):23–32. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science . 1997;275(5306):1593–1599. Nasser HM, Calu DJ, Schoenbaum G, Sharpe MJ. The dopamine prediction error: Contributions to associative models of reward learning. Front Psychol . 2017;8:244. Kahnt T, Schoenbaum G. The curious case of dopaminergic prediction errors and learning associative information beyond value. Nat Rev Neurosci . 2025;26:169–178. Lally P, van Jaarsveld CHM, Potts HWW, Wardle J. How are habits formed: Modelling habit formation in the real world. Eur J Soc Psychol . 2010;40(6):998–1009. American Psychological Association. Harnessing the power of habits. Monitor Psychol . 2020;51(8):78–83.
References: Baddeley A. Working memory: theories, models, and controversies. Annu Rev Psychol . 2012;63:1–29. Chai WJ, Abd Hamid AI, Malin Abdullah J. Working memory from the psychological and neurosciences perspectives: a review. Front Psychol . 2018;9:401. Rogers RD, Monsell S. Costs of a predictable switch between simple cognitive tasks. J Exp Psychol Gen . 1995;124(2):207–231. Rubinstein JS, Meyer DE, Evans JE. Executive control of cognitive processes in task switching. J Exp Psychol Hum Percept Perform . 2001;27(4):763–797. Garner KG, Dux PE. Knowledge generalization and the costs of multitasking. Nat Rev Neurosci . 2023;24:98–112. Zhou X, Lei X. Wandering minds with wandering brain networks. Neurosci Bull . 2018;34(6):1017–1028. Sorella S, Crescentini C, Matiz A, et al. Resting‑state default mode network variability predicts spontaneous mind‑wandering. Front Hum Neurosci . 2025;19:1515902. Sweller J. Cognitive load during problem solving: effects on learning. Cogn Sci . 1988;12(2):257–285.
Why do we procrastinate even when tasks matter most? Discover the emotional roots of procrastination and how to stop
Confidence and self-esteem are often confused but are psychologically distinct. Learn how they differ, how each develops, and why understanding both matters for real growth.
Confidence isn’t about eliminating fear—it’s about acting despite it. Discover how courage, discomfort, and psychological growth build real confidence over time.
References: McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med . 2014;371(11):993–1004. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med . 2007;357:2109–2122. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med . 2008;358:1431–1443. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med . 2008;358:2545–2559. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med . 1991;324:781–788. Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on cardiovascular and renal outcomes. N Engl J Med . 2020;383:1413–1424. Ioannidis JPA. Surrogate endpoints in clinical trials: are we being misled? BMJ . 2013;346:f314.
References: Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, learning and health. Nat Rev Neurosci . 2015;16(7):403‑18. Frisaldi E, Shaibani A, Benedetti F, Pagnini F. Placebo and nocebo effects associated with pharmacological interventions: an umbrella review. BMJ Open . 2023;13:e077243. Colloca L, Finniss D. Nocebo effects, patient‑clinician communication, and therapeutic outcomes. JAMA . 2012;307(6):567‑8. Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a blinded, randomized trial of statin, placebo, and no treatment. N Engl J Med . 2021;385(23):2180‑9. Penson PE, Mancini GBJ, Toth PP, et al. Introducing the “drucebo” effect in statin therapy. J Cachexia Sarcopenia Muscle . 2018;9(6):1023‑33. Barnes K, Faasse K, Geers AL, et al. Can positive framing reduce nocebo side effects? Front Pharmacol . 2019;10:167. Caliskan EB, Bingel U, Kunkel A. Translating knowledge on placebo and nocebo effects into clinical practice. Pain Rep . 2024;9(2):e1142. von Wernsdorff M, Loef M, Tuschen‑Caffier B, Schmidt S. Effects of open‑label placebos in clinical trials: a systematic review and meta‑analysis. Sci Rep . 2021;11:3855.
References: Zaniletti I, Larson DR, Lewallen DG, Berry DJ, Maradit Kremers H. How to distinguish correlation from causation in orthopaedic research. J Arthroplasty. 2023;38(4):634–637. Rush J, Ajami M, Look KA, Margolis A. Statistics review part 10: causality and confounding. J Pharm Soc Wis. 2014;17(1):45–52. Koopmans E, Schiller C. Understanding causation in healthcare: an introduction to critical realism. Qual Health Res. 2022;32(8–9):1207–1214. Kahlert J, Gribsholt SB, Gammelager H, Dekkers OM, Luta G. Control of confounding in the analysis phase – an overview for clinicians. Clin Epidemiol. 2017;9:195–204. Shi AX, Zivich PN, Chu H. A comprehensive review and tutorial on confounding adjustment methods for estimating treatment effects using observational data. Appl Sci (Basel). 2024;14(9):3662. Gao Y, Xiang L, Yi H, Song J, Sun D, Xu B, et al. Confounder adjustment in observational studies investigating multiple risk factors: a methodological study. BMC Med. 2025;23:132. Ho FK, Brown J, Galwey NW. Regression adjustment for causal inference. BMJ Med. 2025;4:e000816. Correia LCL, Mascarenhas RF, Menezes FSC, Oliveira Junior JS, Vaccarino V, Ross JS, et al. Confounder selection in observational studies in high‑impact medical and epidemiological journals. JAMA Netw Open. 2025;8(7):e2524176.